Loading stock data…
Dyne Therapeutics (DYN)
$24.44+0.55 (+2.30%)
Market ClosedLast close Jul 24
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Dyne Therapeutics, Inc. in the Healthcare sector is trading at $24.44 with a market capitalization of $3.0B. Wall Street consensus targets $39.33 (15 analysts), implying a +60.9% move over the next 12 months. The stock is currently near its 52-week high of $25.00, remaining 29.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +60.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$125.28M↓ | -$116.13M↓ | -$113.89M↑ | -$115.79M↑ | -$122.37M |
| Net Income | -$120.85M↓ | -$111.95M↓ | -$108.04M↑ | -$110.86M↑ | -$115.36M |
Peer Comparison
JNJUNHPFE
Fundamentals
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, includi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-52.22%
Volume
Today's trading volume
4.29M
Recent News
Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling?
Dyne Therapeutics (DYN) is back in focus after pricing an upsized follow on equity offering of 18,300,000 common shares at $20.50 each, raising about $375 million in gross proceeds. See our latest analysis for Dyne Therapeutics. Despite the short term pressure from the discounted offering price, with a 1 day share price return of 2.60% lower and a 7 day share price return of 3.25% lower, Dyne Therapeutics still shows strong momentum. The 30 day share price return is 11.21%, the 90 day share...
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Major Tech Earnings
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) retreated 0.4%, and the actively
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)
Discounted share sale weighs on stockDyne Therapeutics, Inc. (NASDAQ:DYN) shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approximately $375 million.
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock
Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.